ARR Q1 2026 Earnings EPS Beats Estimates Amidst a Choppy Rate Environment GNPX Q1 2026 Earnings ClinicalStage Biotech Reports Net Loss with No Revenue Stock Moves Up 074 BGS Q1 2026 Earnings EPS Surpasses Estimates by 457 as Cost Discipline Supports Bottom Line Evaxion Q1 2026 Earnings EPS Widely Misses Estimates as ClinicalStage Biotech Continues Pipeline Investment WFC Q1 2026 Earnings EPS Beats Estimates by a Narrow Margin Stock Edges Higher SYRE Q1 2026 Earnings WiderthanExpected Loss Highlights Development Stage Challenges